Anticardiolipin and anti-beta-2 glycoprotein I antibodies in patients with moderate or severe COVID-19

García-Arellano, Gisela; Camacho-Ortíz, Adrián; Moreno-Arquieta, Ilse Andrea; Garza, Jesús Alberto Cárdenas‐de la; Rubio-Torres, Diana Carolina; Garza‐González, Elvira; Bocanegra‐Ibarias, Paola; Galarza‐Delgado, Dionicio Ángel

doi:10.1016/j.amjms.2022.10.012

Cited by 3 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Besides, we demonstrated, in our recent study, an elevated frequency of aβ2GPI‐IgA in patients with hepatitis C 17 . Garcia‐Arellano et al 30 found that the most frequent aPL was aβ2GPI‐IgA on COVID‐19 patients with a frequency of 73.9%.…”

Section: Discussionsupporting

confidence: 64%

Anticardiolipin and anti‐beta 2‐glycoprotein I antibodies in patients with unexplained articular manifestations

Melayah

Ghozzi

Ghedira

et al. 2022

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Objective To determine the frequency of antiphospholipid antibodies (aPL) in patients with unexplained articular manifestations. Material and Methods Three hundred thirteen patients suffering from arthritis or arthralgia without evident cause and 266 healthy blood donors (HBD) were included in the study. Anticardiolipin antibodies (aCL) and anti‐beta 2‐glycoprotein I antibodies (aβ2GPI) were measured by ELISA. Result Out of the 313 patients, 250 were females and 63 were males. The mean age of patients was 49 ± 14 years (17–87 years). One hundred eleven patients have arthralgia and 202 have arthritis. The frequency of aCL and/or aβ2GPI (24.9%) was significantly higher in patients than in HBD (10.9%). The frequency of aβ2GPI was 23.6% in patients and 9.4% in the control group (p < 10−3). aβ2GPI‐IgA was significantly more frequent in patients than in the control group (20.4% vs. 7.5%, p < 10−3). aβ2GPI was most commonly observed than aCL in patients (23.6% vs. 6.4%, p < 10−6). IgA isotype of aβ2GPI was the most frequent in 20.4% of patients while IgG and IgM were detected in 5.4% and 2.9% respectively. Conclusion This study showed that aPL were common in patients with articular manifestations and were mainly directed against β2GPI. The role of these antibodies remains to be specified.

show abstract

Section: Discussionsupporting

confidence: 64%

Anticardiolipin and anti‐beta 2‐glycoprotein I antibodies in patients with unexplained articular manifestations

Melayah

Ghozzi

Ghedira

et al. 2022

Clinical Laboratory Analysis

View full text Add to dashboard Cite

show abstract

“…У пациента отмечался повышенный уровень антител к β2-гликопротеину. Повышение данного показателя может быть признаком антифосфолипидного синдрома, однако показано повышение его уровня в крови у больных с инфекцией COVID-9 в 73,9% случаев (в особенности IgA), которую пациент перенес [6]. Также есть наблюдения о повышении уровня антител к β2-гликопротеину при ряде других бактериальных и вирусных инфекций [7].…”

Section: Discussionunclassified

A case of development of membranous nephropathy against the background of atypical hemolytic-uremic syndrome activated as a result of acute respiratory viral infection

Batiushin,

Beloborodova,

Korobka

et al. 2023

jour

View full text Add to dashboard Cite

The article considers a clinical case of atypical hemolytic-uremic syndrome, which was the starting mechanism for the development of membranous nephropathy. Patient X. 23 years after acute respiratory viral infection, signs of nephrotic syndrome, arterial hypertension, and impaired kidney function appeared. Puncture nephrobiopsy was performed and the morphological picture corresponds to immunocomplex glomerulonephritis, most likely membranous nephropathy with the presence of segmental glomerulosclerosis, cellular half-moons. In parallel, the patient had verified signs of thrombotic microangiopathy in the form of microangiopathic anemia, thrombocytopenia, increased lactate dehydrogenase levels as a sign of cytolysis (primarily intravascular hemolysis). During the differential diagnosis, we stopped at the diagnosis of atypical hemolytic-uremic syndrome. The uniqueness of the described clinical case is that cases of glomerulonephritis against the background of atypical hemolytic-uremic syndrome are extremely rare, and membranous nephropathy is described for the first time.

show abstract

IgA Anti-β2-Glycoprotein I Antibodies as Markers of Thrombosis and Severity in COVID-19 Patients

Mellor-Pita,

Tutor-Ureta,

Velasco

et al. 2024

Viruses

View full text Add to dashboard Cite

Patients with COVID-19 may develop a hypercoagulable state due to tissue and endothelial injury, produced by an unbalanced immune response. Therefore, an increased number of thromboembolic events has been reported in these patients. The aim of this study is to investigate the presence of antiphospholipid antibodies (aPL) in COVID-19 patients, their role in the development of thrombosis and their relationship with the severity of the disease. In this retrospective study, serum samples from 159 COVID-19 patients and 80 healthy donors were analysed for the presence of aPL. A total of 29 patients (18.2%) and 14 healthy donors (17.5%) were positive for aPL. Nineteen COVID-19 patients (12%) but no healthy donor presented a positive percentage of the IgA isotype aPL. IgA anti-β2-glycoprotein I antibodies (anti-β2GPI) were the most frequent type (6.3%) in patients but was not detected in any healthy donor. The positivity of this antibody was found to be significantly elevated in patients with thromboembolic events (25% vs. 5%, p = 0.029); in fact, patients with positive IgA anti-β2GPI had an incidence of thrombosis over six times higher than those who had normal antibody concentrations [OR (CI 95%) of 6.67 (1.5–30.2), p = 0.014]. Additionally, patients with moderate-severe disease presented a higher aPL positivity than patients with mild disease according to the Brescia (p = 0.029) and CURB-65 (p = 0.011) severity scales. A multivariate analysis showed that positivity for IgA anti-β2GPI is significantly associated with disease severity measured by CURB-65 [OR (CI 95%) 17.8 (1.7–187), p = 0.0016]. In conclusion, COVID-19 patients have a significantly higher positive percentage of the IgA isotype aPL than healthy donors. IgA anti-β2GPI antibodies were the most frequently detected aPL in COVID-19 patients and were associated with thrombosis and severe COVID-19 and are thus proposed as a possible marker to identify high-risk patients.

show abstract

Anticardiolipin and anti-beta-2 glycoprotein I antibodies in patients with moderate or severe COVID-19

Cited by 3 publications

References 9 publications

Anticardiolipin and anti‐beta 2‐glycoprotein I antibodies in patients with unexplained articular manifestations

Anticardiolipin and anti‐beta 2‐glycoprotein I antibodies in patients with unexplained articular manifestations

A case of development of membranous nephropathy against the background of atypical hemolytic-uremic syndrome activated as a result of acute respiratory viral infection

IgA Anti-β2-Glycoprotein I Antibodies as Markers of Thrombosis and Severity in COVID-19 Patients

Contact Info

Product

Resources

About